API | alvircept sudotox

alvircept sudotox Report issue

Biologics Recombinant protein Experimental

AACT ChEMBL DrugBank

Active Ingredient History

NOW

Alvircept sudotox is a form of recombinant CD4 derived from Pneumonas aeruginosa exotoxin A, or 'PE40, which has a size of 59,187 daltons and is an anti-viral agent. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
alvircept sudotox

More Chemistry

Pharmacology

Mechanism of Action:
- T-cell surface glycoprotein CD4 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

alvircept sudotox | scd4-pe40 | u-85855

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

HIV Infections (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 2
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue